Abstract Objective Apathy is a prevalent and clinically consequential neuropsychiatric syndrome across neurological disorders, yet its assessment remains conceptually and methodologically challenging. This narrative review synthesizes current knowledge on the measurement of apathy, with particular emphasis on apathy-specific instruments validated in neurological populations and on the theoretical and practical factors that constrain their clinical utility. Method Literature was identified through PubMed searches, citation tracking, and review of influential consensus statements and neurocognitive models. Instruments were critically examined with regard to their conceptual foundations, psychometric properties, and ecological validity in clinical neuropsychological contexts. Results Despite broad agreement that apathy is a multidimensional construct, many widely used instruments retain predominantly unidimensional structures or show limited alignment with contemporary models, contributing to suboptimal discriminant validity—particularly in relation to depression—and inconsistent agreement across self-, informant-, and clinician-based assessments. Additional sources of bias include contextual and sensorimotor constraints, such as institutional environments and motor disability, which may inflate behavioral ratings and obscure primary motivational deficits. Conclusions Recent advances, including dimensional and context-sensitive approaches, represent promising developments; however, improving diagnostic precision and clinical decision-making requires integrating standardized rating scales with complementary paradigms targeting core motivational processes, such as effort-based decision-making, reward anticipation, and emotional responsiveness. Greater conceptual consensus, clearer construct boundaries, improved cross-cultural adaptation, and more consistent reporting practices are essential to enhance comparability across studies and to support clinical neuropsychologists involved in differential diagnosis, longitudinal monitoring, and treatment planning in neurological populations.
Noreña-Martínez et al. (Tue,) studied this question.